Clinician’s Guide: Immunotherapy for Metastatic Merkel Cell Carcinoma

In this downloadable resource, expert faculty Paul Nghiem, MD reviews the rationale for and key data supporting the use of immune checkpoint inhibitors in the treatment of MCC. For additional in-depth analysis, please review the accompanying CME-certified text module, downloadable slides, and ClinicalThought commentaries, as well as our interactive algorithm tool for expert guidance with managing immune-related adverse events.
Format: Adobe Acrobat (.pdf)
File Size: 177 KB
Released: March 6, 2017

Acknowledgements

This activity is supported by an educational grant from
Pfizer Inc.
Merck KGaA

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue